Headache
-
The goal of this study was to determine whether the physiological effects of carbon dioxide (CO(2)) involve regulation of CGRP secretion from trigeminal sensory neurons. ⋯ Results from this study provide the first evidence of a unique regulatory mechanism by which CO(2) inhibits sensory nerve activation, and subsequent neuropeptide release. Furthermore, the observed inhibitory effect of CO(2) on CGRP secretion likely involves modulation of calcium channel activity and changes in intracellular pH.
-
Migraine is a common neurological disorder, the origins of which remain unknown. Patent foramen ovale (PFO) is considered to have a role in migraine. The relationship between migraine and patent foramen ovale may be stronger in patients suffering from migraine with aura compared to patients with common migraine. ⋯ Our findings suggest possible association of migraine with aura and PFO. It seems that PFO does not influence the type of aura and frequency of attacks of migraine as well as it is not associated with familial occurrence of migraine.
-
This study examined factors that may predispose migraine patients to emergency department (ED) visits. ⋯ Patient demographics and health care resource availability significantly affected the likelihood of ED use of diagnosed migraine patients. Additional research is needed for the undiagnosed migraine population to inform the development of interventions to reduce ED utilization for migraines.
-
Meta Analysis
Meta-analysis examining the efficacy and safety of almotriptan in the acute treatment of migraine.
To evaluate the comparative efficacy and safety of oral almotriptan in treating acute migraine attacks. ⋯ Almotriptan 12.5 mg is an effective treatment for acute attacks of migraine, in particular, it has been found to be as effective as sumatriptan 100 mg and zolmitriptan 2.5 mg. The risk of adverse events associated with almotriptan 12.5 mg was similar to placebo and significantly lower than sumatriptan 100 mg. Further research is required to assess the comparative efficacy of almotriptan against other triptans.